Cadila Pharmaceuticals Launches Rituximab and Bevacizumab Biosimilars

BioSimilars Blog

On July 29, 2020, Cadila Pharmaceuticals announced its launch of Rituximab biosimilar Ritucad for the Indian market.  Rituximab is used to treat certain types of blood cancers and rheumatoid arthritis.

 Ritucad was the Indian pharmaceutical company’s second biosimilar launch in July.  On July 22, 2020, Cadila announced the launch of Bevaro, a Bevacizumab biosimilar.  Bevacizumab is used to treat multiple cancers, including ovarian, cervical, breast, and lung cancer.

 Cadila reported that it is strengthening its biosimilar portfolio and intends to launch more biosimilar products in the future.